UNSPSC 51351618: Ormeloxifene or centchroman

This classification denotes an antiestrogen with the molecular formula C30H35NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44AXY5VE90, chemically known as 3,4-trans-2,2-dimethyl-3-phenyl-4-(p-(beta-pyrrolidinoethoxy)phenyl)-7-methoxychroman but generally known as ormeloxifene, which bears US NIH Compound Identifier 35805. European Medicines Agency schedules Ormeloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09462MIG.

UNSPSC 51351618 Ormeloxifene or centchroman is a Commodity code representing a specific pharmaceutical active ingredient used in hormonal contraceptive and gynecological applications. State and local governments procure this product primarily as part of broader multi-source pharmaceutical supply agreements serving public health departments, clinics, correctional facilities, and other government-operated medical services. The scope encompasses the active pharmaceutical ingredient itself supplied through established pharmaceutical wholesalers and distribution networks, with vendors required to meet FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance. Issuing bodies soliciting under this code span state health departments and multistate cooperative purchasing alliances, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) emerging as a significant buyer coordinating procurement across participating state and local government facilities in multiple states including Oregon.

Recent activity shows concentration in multistate cooperative purchasing vehicles. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP in January 2026 (Solicitation S1070000015802) titled "MMCAP Generic Multi Source Pharmaceuticals and OTC Products," with proposals due March 26, 2026. This procurement establishes multiple contracts for generic and over-the-counter pharmaceuticals distributed across participating state and local government facilities, with awarded vendors required to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—by May 15, 2026 for a July 1, 2026 contract effective date. The evaluation weights price competitiveness at 75 percent, with scoring also considering fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5 million per occurrence and establish contractual relationships with at least two of the three authorized wholesalers.